Mesoblast Limited (MESO) Receiving Favorable Media Coverage, Study Finds
Headlines about Mesoblast Limited (NASDAQ:MESO) have been trending positive recently, Accern reports. Accern ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Mesoblast Limited earned a news impact score of 0.26 on Accern’s scale. Accern also gave press coverage about the company an impact score of 46.9937003798529 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the news stories that may have effected Accern’s rankings:
- Zacks Investment Research Lowers Mesoblast Limited (MESO) to Strong Sell (americanbankingnews.com)
- Book to Market in Perspective for Mesoblast Limited (ASX:MSB) – Collins Courier (collinscourier.com)
- Mesoblast Limited Forecasted to Earn Q2 2018 Earnings of ($0.19) Per Share (MESO) (americanbankingnews.com)
- Looking at the Numbers for Mesoblast Limited (ASX:MSB) – SCY News (scynews.com)
- Chairman’s Address to the Mesoblast 2017 Annual General Meeting Australian Stock Exchange:MSB.AX (menafn.com)
MESO has been the subject of a number of research analyst reports. BidaskClub downgraded Mesoblast Limited from a “sell” rating to a “strong sell” rating in a report on Friday, July 28th. Maxim Group set a $14.00 price objective on Mesoblast Limited and gave the company a “buy” rating in a research note on Wednesday, August 16th. Oppenheimer Holdings, Inc. began coverage on Mesoblast Limited in a research note on Thursday, August 31st. They issued an “outperform” rating and a $16.00 price objective for the company. Cantor Fitzgerald reissued a “buy” rating and issued a $20.00 price objective on shares of Mesoblast Limited in a research note on Wednesday, August 30th. Finally, ValuEngine cut Mesoblast Limited from a “hold” rating to a “sell” rating in a research note on Friday, September 15th. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $13.14.
Mesoblast Limited Company Profile
Receive News & Stock Ratings for Mesoblast Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast Limited and related stocks with our FREE daily email newsletter.